CV Therapeutics
Executive Summary
Former Syntex Exec VP Thomas Gutshall will come on board in January as president of the molecular cardiology biopharmaceutical R&D company based in Palo Alto, Calif. He will report to Chairman and CEO Louis Lange, MD/PhD